Arcellx Inc

NASDAQ:ACLXUnited States

Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).

Contact Information

Headquarters

800 Bridge ParkwayREDWOOD CITY, CA, United States 94065

Phone

240-327-0603

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Rami Elghandour

Chief Financial Officer

Michelle Gilson

Chief Medical Officer

Christopher Heery

Chief Commercial Officer

Neeraj Teotia

Independent Director

Ali Behbahani